Thomas Dubensky

Thomas Dubensky

Directeur Général chez
ImmuneSensor Therapeutics, Inc.
68 ans
Health Technology
Commercial Services
Consumer Services

Profil

Thomas W.
Dubensky
was the founder of Anza Therapeutics, Inc. (2007), holding the title of Chief Scientific Officer in 2010.
Dr. Dubensky is the founder of ImmuneSensor Therapeutics, Inc., serving as President, Chief Executive Officer & Director since 2024.
Former positions include Chief Executive Officer & Director at TempestTx, Inc., Scientific Director at Chiron Corp., Director at HTG Molecular Diagnostics, Inc. (2022-2023), President & Director at Tempest Therapeutics, Inc. (2017-2023), Vice President at Onyx Pharmaceuticals, Inc., Vice President-Research at Cerus Corp.
(2002-2007), Chief Scientific Officer at Aduro BioTech, Inc. (2011-2017), Principal at Chiron Viagene, Inc., and Chief Scientific Officer at Immune Design Corp.
Education includes an undergraduate degree from the University of California, Berkeley and a doctorate from the University of Colorado Health Sciences Center.

Postes actifs de Thomas Dubensky

SociétésPosteDébut
Directeur Général 01/05/2024

Anciens postes connus de Thomas Dubensky

SociétésPosteFin
TEMPEST THERAPEUTICS, INC. President 15/09/2023
HTG MOLECULAR DIAGNOSTICS, INC. Directeur/Membre du Conseil 01/08/2023
CHINOOK THERAPEUTICS, INC. Directeur Technique/Scientifique/R&D 31/08/2017
CERUS CORPORATION Directeur Technique/Scientifique/R&D 16/11/2007
Directeur Général -
Voir l'expérience en détail de Thomas Dubensky

Formation de Thomas Dubensky

Expériences
Fonctions occupées

Actives

Inactives

Sociétés cotées

Entreprise privées

Relations

29

Relations au 1er degré

13

Entreprises liées au 1er degré

Homme

Femme

Administrateurs

Exécutifs

Sociétés liées

Entreprise privées13

Health Technology

Health Technology

Health Technology

Commercial Services

Health Technology

Health Technology

Commercial Services

Consumer Services

Consumer Services

Health Technology

Health Technology

Commercial Services

Health Technology

  1. Bourse
  2. Insiders
  3. Thomas Dubensky
🔇